Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC Attack in retinitis pigmentosa
NL-OMON59550Phase 3Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in retinitis pigmentosa (RP) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Cumulative loss of ellipsoid zone width. Started Mar 2024; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NL-OMON59550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59550.